Literature DB >> 27900420

NMR-based metabolomic approach to study urine samples of chronic inflammatory rheumatic disease patients.

Alessia Vignoli1, Donatella Maria Rodio2, Anna Bellizzi3, Anatoly Petrovich Sobolev4, Elena Anzivino2, Monica Mischitelli2, Leonardo Tenori5, Federico Marini6, Roberta Priori7, Rossana Scrivo7, Guido Valesini8, Ada Francia9, Manuela Morreale9, Maria Rosa Ciardi2, Marco Iannetta2, Cristiana Campanella10, Donatella Capitani4, Claudio Luchinat1,11, Valeria Pietropaolo2, Luisa Mannina4,10.   

Abstract

The nuclear magnetic resonance (NMR)-based metabolomic approach was used as analytical methodology to study the urine samples of chronic inflammatory rheumatic disease (CIRD) patients. The urine samples of CIRD patients were compared to the ones of both healthy subjects and patients with multiple sclerosis (MS), another immuno-mediated disease. Urine samples collected from 39 CIRD patients, 25 healthy subjects, and 26 MS patients were analyzed using 1H NMR spectroscopy, and the NMR spectra were examined using partial least squares-discriminant analysis (PLS-DA). PLS-DA models were validated by a double cross-validation procedure and randomization tests. Clear discriminations between CIRD patients and healthy controls (average diagnostic accuracy 83.5 ± 1.9%) as well as between CIRD patients and MS patients (diagnostic accuracy 81.1 ± 1.9%) were obtained. Leucine, alanine, 3-hydroxyisobutyric acid, hippuric acid, citric acid, 3-hydroxyisovaleric acid, and creatinine contributed to the discrimination; all of them being in a lower concentration in CIRD patients as compared to controls or to MS patients. The application of NMR metabolomics to study these still poorly understood diseases can be useful to better clarify the pathologic mechanisms; moreover, as a holistic approach, it allowed the detection of, by means of anomalous metabolic traits, the presence of other pathologies or pharmaceutical treatments not directly connected to CIRDs, giving comprehensive information on the general health state of individuals. Graphical abstract NMR-based metabolomic approach as a tool to study urine samples in CIRD patients with respect to MS patients and healthy controls.

Entities:  

Keywords:  Chronic inflammatory rheumatic diseases; Metabolomics; Multivariate data analysis; Nuclear magnetic resonance spectroscopy; Urine

Mesh:

Year:  2016        PMID: 27900420     DOI: 10.1007/s00216-016-0074-z

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  11 in total

1.  NMR-Based Metabolomics in Differential Diagnosis of Chronic Kidney Disease (CKD) Subtypes.

Authors:  Styliani A Chasapi; Evdokia Karagkouni; Dimitra Kalavrizioti; Sotirios Vamvakas; Aikaterini Zompra; Panteleimon G Takis; Dimitrios S Goumenos; Georgios A Spyroulias
Journal:  Metabolites       Date:  2022-05-28

Review 2.  Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer.

Authors:  Alessia Vignoli; Emanuela Risi; Amelia McCartney; Ilenia Migliaccio; Erica Moretti; Luca Malorni; Claudio Luchinat; Laura Biganzoli; Leonardo Tenori
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

3.  Metabolomics of Hydrazine-Induced Hepatotoxicity in Rats for Discovering Potential Biomarkers.

Authors:  Zhuoling An; Chao Li; Yali Lv; Pengfei Li; Cheng Wu; Lihong Liu
Journal:  Dis Markers       Date:  2018-04-10       Impact factor: 3.434

4.  NMR-based metabolomics identifies patients at high risk of death within two years after acute myocardial infarction in the AMI-Florence II cohort.

Authors:  Alessia Vignoli; Leonardo Tenori; Betti Giusti; Panteleimon G Takis; Serafina Valente; Nazario Carrabba; Daniela Balzi; Alessandro Barchielli; Niccolò Marchionni; Gian Franco Gensini; Rossella Marcucci; Claudio Luchinat; Anna Maria Gori
Journal:  BMC Med       Date:  2019-01-07       Impact factor: 8.775

Review 5.  Metabolomics profile in gastrointestinal cancers: Update and future perspectives.

Authors:  Giulia Nannini; Gaia Meoni; Amedeo Amedei; Leonardo Tenori
Journal:  World J Gastroenterol       Date:  2020-05-28       Impact factor: 5.742

6.  Differential Network Analysis Reveals Molecular Determinants Associated with Blood Pressure and Heart Rate in Healthy Subjects.

Authors:  Alessia Vignoli; Leonardo Tenori; Claudio Luchinat; Edoardo Saccenti
Journal:  J Proteome Res       Date:  2020-12-04       Impact factor: 4.466

7.  Relationship Between Inflammation and Metabolism in Patients With Newly Presenting Rheumatoid Arthritis.

Authors:  Gurpreet Singh Jutley; Kalvin Sahota; Ilfita Sahbudin; Andrew Filer; Thurayya Arayssi; Stephen P Young; Karim Raza
Journal:  Front Immunol       Date:  2021-09-28       Impact factor: 7.561

Review 8.  High-Throughput Metabolomics by 1D NMR.

Authors:  Alessia Vignoli; Veronica Ghini; Gaia Meoni; Cristina Licari; Panteleimon G Takis; Leonardo Tenori; Paola Turano; Claudio Luchinat
Journal:  Angew Chem Int Ed Engl       Date:  2018-11-11       Impact factor: 15.336

9.  Differential Network Analysis Reveals Metabolic Determinants Associated with Mortality in Acute Myocardial Infarction Patients and Suggests Potential Mechanisms Underlying Different Clinical Scores Used To Predict Death.

Authors:  Alessia Vignoli; Leonardo Tenori; Betti Giusti; Serafina Valente; Nazario Carrabba; Daniela Balzi; Alessandro Barchielli; Niccolò Marchionni; Gian Franco Gensini; Rossella Marcucci; Anna Maria Gori; Claudio Luchinat; Edoardo Saccenti
Journal:  J Proteome Res       Date:  2020-01-17       Impact factor: 4.466

10.  Effects of a Diet Based on Foods from Symbiotic Agriculture on the Gut Microbiota of Subjects at Risk for Metabolic Syndrome.

Authors:  Silvia Turroni; Elisabetta Petracci; Valeria Edefonti; Anna M Giudetti; Federica D'Amico; Lisa Paganelli; Giusto Giovannetti; Laura Del Coco; Francesco P Fanizzi; Simone Rampelli; Debora Guerra; Claudia Rengucci; Jenny Bulgarelli; Marcella Tazzari; Nicoletta Pellegrini; Monica Ferraroni; Oriana Nanni; Patrizia Serra
Journal:  Nutrients       Date:  2021-06-17       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.